Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Losartan Potassium
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kwality Pharma Gains on Securing RCGM Approval for Erythropoietin
Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 02, 2025
Lead Product(s) : Losartan Potassium
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tamoxifen Citrate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kwality Pharma Gains on Securing SAHPRA Approval for Tamoxifen Tablet
Details : Tamoxifen is a small molecule acts as an Estrogen receptor modulator, which is being investigated for the treatment of hormone receptor-positive breast cancer.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 23, 2024
Lead Product(s) : Tamoxifen Citrate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kwality Pharma Gains Greece Approval for Leuprorelin Acetate Injectable Suspension
Details : Luprodex (leuprorelin acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for palliative treatment of advanced prostatic cancer.
Product Name : Luprodex
Product Type : Peptide
Upfront Cash : Not Applicable
November 07, 2024
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable